The Food and Drug Administration approved Johnson & Johnson’s nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.
The spray, called Spravato, is now the first-ever standalone therapy for treatment-resistant depression, which is when trying at least two standard treatments does little to nothing to improve depression symptoms in a patient.
Spravato is on its way to becoming a blockbuster product, with the drug bringing in $780 million in sales during the first nine months of 2024 as doctors grow more comfortable using it.
